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Abstract
Background: Insertional mutagenesis screens have been used with great success to identify oncogenes and tumor
suppressor genes. Typically, these screens use gammaretroviruses (γRV) or transposons as insertional mutagens.
However, insertional mutations from replication-competent γRVs or transposons that occur later during oncogenesis
can produce passenger mutations that do not drive cancer progression. Here, we utilized a replication-incompetent
lentiviral vector (LV) to perform an insertional mutagenesis screen to identify genes in the progression to
androgen-independent prostate cancer (AIPC).
Methods: Prostate cancer cells were mutagenized with a LV to enrich for clones with a selective advantage in an
androgen-deficient environment provided by a dysregulated gene(s) near the vector integration site. We performed
our screen using an in vitro AIPC model and also an in vivo xenotransplant model for AIPC. Our approach identified
proviral integration sites utilizing a shuttle vector that allows for rapid rescue of plasmids in E. coli that contain LV
long terminal repeat (LTR)-chromosome junctions. This shuttle vector approach does not require PCR amplification
and has several advantages over PCR-based techniques.
Results: Proviral integrations were enriched near prostate cancer susceptibility loci in cells grown in androgen-
deficient medium (p < 0.001), and five candidate genes that influence AIPC were identified; ATPAF1, GCOM1, MEX3D,
PTRF, and TRPM4. Additionally, we showed that RNAi knockdown of ATPAF1 significantly reduces growth (p < 0.05)
in androgen-deficient conditions.
Conclusions: Our approach has proven effective for use in PCa, identifying a known prostate cancer gene, PTRF,
and also several genes not previously associated with prostate cancer. The replication-incompetent shuttle vector
approach has broad potential applications for cancer gene discovery, and for interrogating diverse biological and
disease processes.
Keywords: Prostate cancer, Lentiviral vector, Mutagenesis screen, Shuttle vector, Androgen-independent prostate
cancer, Proto-oncogene
Background
Insertional mutagenesis screens using replicating retrovi-
ruses have identified many genes that contribute to can-
cer initiation and progression and have greatly improved
our understanding of carcinogenesis (reviewed by Uren
et al. [1]). These screens identify genomic loci which
contain proviral integration sites that are identified from
different tumors, called common insertion sites (CISs).
These CISs occur because integrated retroviruses dysre-
gulate nearby genes by a variety of mechanisms, and
clones with provirus insertions near dysregulated genes
that provide a selective advantage become enriched [2].
To date, the majority of insertional mutagenesis screens
have utilized replicating gammaretroviruses (γRV) or
transposons which have several limitations. Screens that
use replicating retroviruses are limited to tissues and cell
types that are permissive for replication of the virus. Be-
cause of this, the majority of screens have been performed
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in mouse hematopoietic cells or mouse mammary cells
using replicating γRV vectors. Transposons allow muta-
genesis of essentially any tissue and have expanded the
use of mutagenesis screens. However, a major drawback of
transposon approaches is the time it takes to generate the
germline transgenic or knockout lines used, and to
combine multiple alleles into the same background
[3]. Another limitation of transposon mutagenesis is
that multiple transposition events complicate the identifi-
cation of causative mutagenic events [3].
One way to greatly expand the potential of forward
mutagenesis screens is to use replication-incompetent
lentiviral vectors (LVs) [4]. Human immunodeficiency
virus (HIV)-derived LVs that are pseudotyped with the
vesicular stomatitis virus glycoprotein can efficiently
transduce essentially all mammalian cell types. Replication-
incompetent LVs integrate into the genome but do not rep-
licate, and thus do not create additional insertion sites.
Therefore, there are fewer potential passenger integrations
than with replication-competent vectors, where driver in-
sertional mutation events may be masked by the accumu-
lation of bystander integrations [4,5]. Also the level of
mutagenesis can be carefully controlled by adjusting the
multiplicity of infection. Importantly, under the right con-
ditions replication-competent vectors can cause cancer,
which was unfortunately observed in gene therapy
studies where replication-incompetent γRV vectors caused
leukemia [6,7].
Here we report a novel screen to identify genes in the
progression to androgen-independent prostate cancer
(AIPC) in human cells using a replication-incompetent
HIV-based LV. Prostate cancer (PCa) is the second most
common cause of cancer related deaths in men in the
United States, and is one of the leading causes of sick-
ness and death in men in the U.S. and Western Europe
[8,9]. Despite this high prevalence, the molecular mecha-
nisms of PCa progression still remain largely unknown,
due in part to heterogeneity during tumor development
[10]. PCa is initially androgen-dependent, making andro-
gen deprivation therapy the first line of defense in com-
bating the disease [11]. Though this treatment initially
reduces tumor size, patients eventually develop AIPC,
which is resistant to this primary form of therapy and is
ultimately lethal [11-13]. Thus, determining the mecha-
nisms that contribute to AIPC is critical to develop
novel therapies for this advanced form of PCa. The
current study was designed to identify genes involved in
the progression to AIPC. The human LNCaP PCa cell
line model for AIPC is well-established [11,14,15]. LNCaP
cells express androgen receptor, prostate-specific antigen,
and generate androgen-independence by distinct mecha-
nisms [11,15]. Additionally, LNCaP cells readily form tu-
mors in immunodeficient mice allowing in vivo studies
[16,17]. A transposon-based mutagenesis screen has been
performed for PCa that specifically investigated PCa pre-
cursor lesions and genes that were involved in PCa initi-
ation, but AIPC mechanisms were not investigated [18].
A major advantage of our approach is the use of a
LV shuttle vector that allows rescue of vector LTR-
chromosome junctions in bacteria as plasmids. In other
retroviral and transposon-based screens, PCR is typically
used to recover these proviral insertions and in turn detect
dysregulated genes [1,19]. However, PCR lacks the sensi-
tivity to detect integrations events that are rare or poorly
amplified. It has previously been suggested that plasmid-
based rescue of the provirus integration might eventually
replace PCR methods [1]. Our study demonstrates the po-
tential of this approach in a mutagenesis screen for AIPC.
Results
Efficient LV transduction results in a library of
mutagenized PCa cells where clonality can be rapidly
assessed by shuttle vector rescue
To identify candidate genes involved in the progression
to AIPC we used a replication-incompetent LV, LV-
SFFVEGFP (Figure 1A) that has a strong spleen focus-
forming virus promoter known to dysregulate genes
[20], and also includes a bacterial origin of replication
and a kanamycin resistance gene to allow identification
of integration sites by rescue of shuttle vector plasmids
in E. coli. Our approach uses random shearing of gen-
omic DNA to avoid restriction site bias [21] and does
not require any PCR amplification so it also eliminates
PCR-based bias. The LV expresses EGFP gene from the
spleen focus-forming virus promoter, allowing for effi-
cient tracking of transduced cells in vitro and in vivo
(Figure 1B). The androgen-dependent human PCa cell line,
LNCaP, was transduced in triplicate with LV-SFFVEGFP
resulting in three independent cultures of LNCaP cells de-
noted shuttle vector-mutagenized (SVM) -A, -B, and -C.
The transduction frequency was over 99% as assessed by
EGFP expression.
The clonality of these cultures prior to selection for
androgen independence was evaluated to ensure that
cells used for the mutagenesis screen were polyclonal.
We reasoned that a highly polyclonal pool of integra-
tions, in essence a library, would improve the ability of
our screen to identify AIPC progression genes. High-
throughput sequencing of shuttle vector rescued plas-
mids was performed to identify provirus-chromosome
junctions (Figure 1C,D). Sequences were aligned to the
human genome to identify the provirus integration site
in the human genome. A clonality calculation was per-
formed to approximate the number of unique integ-
rations present in each sample prior to selection for
androgen-independence. By counting both the number
of new integration sites in each survey, and accounting
for the number of previously identified integration sites,
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the approximate number of unique integration sites in a
population could be calculated. A sample calculation for
SVM-A is shown in Additional file 1: Figure S1. In this
example, five surveys were performed and a clonality of
7.2 × 103 unique integration sites was calculated. The
more surveys that are performed, the larger N will be-
come, improving the accuracy of the clonality estimate, so
this is a minimum estimate. Clonality was similar for cul-
tures SVM-B and SVM-C. Sequencing confirmed that
there was no evidence of cross contamination between in-
dependent cultures, as no identical integration sites were
identified between the three mutagenized cultures. These
data showed that we had a highly polyclonal starting po-
pulation prior to selection for androgen independence.
In vitro screen to identify genes that influence androgen-
independence
To model the clinical progression to advanced AIPC
[22] in vitro we used a previously established method to
select for cells that become androgen-independent in
culture [11,14,15]. In this model androgen-dependent
LNCaP cells are cultured in charcoal/dextran-treated
fetal bovine serum (CT-FBS) which is essentially devoid
of androgen. This selects for those cell clones that have
a proliferative advantage in an androgen-deficient envir-
onment (Figure 1B). The human LNCaP cell line has
several advantages for our screen including expression
of androgen receptor, androgen-dependent growth, a
demonstrated ability to develop androgen-independent
growth [11,14,15], and the ability to form tumors in vivo
[16,23] to allow us to explore genes and gene pathways
that mediate progression in vivo. Preliminary experi-
ments showed that transfer of LNCaP cells into media
supplemented with 10% CT-FBS led to a loss of cells
which would have reduced the clonality of our LV-
mutagenized library of insertion sites. We found that ini-
tial culture in 9.75% CT-FBS with 0.25% untreated FBS
minimized cell loss. We thus cultured LV-mutagenized
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Figure 1 LV-mediated mutagenesis screen. A) Schematic of LV-SFFVEGFP vector. The strong spleen focus-forming viral (SFFV) promoter drives
the expression of enhanced green fluorescent protein (EGFP). The vector includes a R6Kγ origin of replication (R6Kori) and kanamycin resistance
gene (KanR) for rescue in E.coli. Both long terminal repeats are self-inactivating (SIN.LTR). B) Experimental outline for in vitro LV-mediated
insertional mutagenesis screen. Mutagenized sample (SVM-A) became androgen-independent before control, non-mutagenized cells. At this time
genomic DNA was extracted and analyzed by our shuttle vector rescue approach. C) Shuttle vector rescue. Genomic DNA is sheared into smaller
fragments. The ends are polished and the fragments are ligated into plasmids. Plasmids are transformed into electrocompetent E. coli. Using an
LTR-specific primer, the junction between the provirus LTR and the chromosome DNA is sequenced. D) To identify the proviral integration site
the chromosomal DNA at the junction is used as a query and aligned to the human genome to identify the integration site.
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and control cells in media supplemented with 9.75%
CT-FBS with 0.25% untreated FBS for approximately
140 days prior to moving cultures to media supple-
mented with 10% CT-FBS. At this time shuttle-vector
mutagenized androgen-dependent LNCaP cells were
maintained in an androgen-deficient environment with
CT-FBS. After 211 days, the SVM-A culture showed an
increase in growth rate compared to control cultures,
and was deemed androgen-independent (Figure 1B). We
hypothesized that in the SVM-A culture, cells with LV
proviruses near genes that influenced progression to AIPC
had a selective advantage and this led to androgen-
independent growth in the SVM-A culture prior to
control cultures. This is expected to lead to an over-
representation of cells with proviral integrants near
genes that influence AIPC. Thus, analysis of provirus
integration sites in these androgen-independent cells
should identify dysregulated genes near vector proviruses
that may mediate progression to AIPC. Genomic DNA
was isolated from LV-transduced androgen-independent
cells to identify candidate AIPC progression genes by
shuttle vector rescue (Figure 1C).
In vivo xenotransplant approach to identify genes that
influence androgen-independence
In vitro models lack the ability to identify genes involved
in processes required only in vivo such as vasculari-
zation. We thus also performed our LV shuttle vector
screen in vivo using a LNCaP xenograft model [16,23].
NOD.Cg-PrkdcscidIl2rgtmlWjl/SzJ (NSG) mice are se-
verely immunocompromised, and allow for efficient
engraftment of human cells [24]. Androgen-dependent
control LNCaPs and mutagenized SVM-A cells prior to
selection in vitro were injected into male NSG mice
(Figure 2A). Tumors developed from the injection of both
SVM-A and control LNCaP cells. Similar to androgen-
dependent tumors in PCa patients, it was expected that
tumor volumes would regress following androgen dep-
rivation therapy. In patients, this is done by either a surgi-
cal or chemical castration [22]. In the in vivo model, this
environment was created by surgical removal of the testes
which are the primary source of androgens. It was ex-
pected that tumor size would decrease immediately
following castration and similar to the in vitro model,
the androgen-deficient environment would select for
androgen-independent cells modeling what occurs in
PCa patients [11,12]. LNCaP cells were injected in male
NSG mice and formed in 6 of 7 injected mice (Figure 2B).
Tumors did regress following castration and following the
castration, tumor growth resumed. Tumors were allowed
to grow until they reached volumes larger than the tumor
size prior to castration, at which point tumors were har-
vested and genomic DNA was obtained for shuttle vector
rescue analysis.
Identification of genes near LV integration sites isolated
from in vitro androgen-independent cultures and
subcutaneous tumors from castrated mice
Rescue of genomic DNA from the androgen-independent
culture SVM-A in vitro samples post-selection recovered
a total of 21 unique sites (Additional file 2: Table S1).
From two in vivo tumors analyzed post-castration we
identified a total of 54 insertion sites, 27 from one tumor
and 28 from the second with one site found in both tu-
mors (Additional file 2: Table S1). All sites were single in-
sertion sites. Custom PERL computer programs were used
to analyze whether the provirus integrated within a RefSeq
gene and to also provide the distance from the integration
site to the nearest 3 Refseq gene transcription start sites
(TSS). Only genes that had a TSS within 100 kb of the
vector provirus were considered.
Enrichment of vector proviruses within PCa susceptibility
loci after selection for androgen-independence
We hypothesized that our approach should enrich for
vector integration sites near regions known to be involved
in PCa progression. The 75 integration sites (Additional
file 2: Table S1) were mapped relative to previously de-
scribed PCa susceptibility loci (Additional file 3: Table S2)
and compared to 412 control integration sites ob-
tained from transduced LNCaP cells prior to selection
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Figure 2 In vivo LV-mediated insertional mutagenesis screen.
A) In vivo approach. Mice were injected with shuttle-vector
mutagenized LNCaPs subcutaneously in the right flank. Following
tumor development, mice were castrated and the tumors regressed.
Following castration tumors regressed in most mice. When the
tumor re-grew to larger than pre-castration size, the tumor was
removed, genomic DNA was extracted, and shuttle vector rescue
was performed. B) Tumor growth in vivo. Animals were castrated
between days 40-50 as indicated by the arrow.
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for androgen-independence, and also to a random in
silico generated data set of 10,000 sites (Figure 3).
The percent of vector integrations within PCa susceptibil-
ity loci for LNCaP cells cultured in androgen-deficient
medium was significantly higher than from the LNCaP
cells prior to culture in androgen-deficient culture me-
dium (p < .001) and also significantly higher than from the
random sites (p < .001). This demonstrates a significant
enrichment of vector proviruses near loci previously asso-
ciated with PCa when cells are grown under androgen-
deficient conditions.
Meta-analysis of expression of candidate PCa genes near
vector proviruses
We used data from previously published microarray ana-
lysis of patient tumors to identify the genes in our data-
set that were most likely to contribute to AIPC based on
dysregulation in patient tumors. This approach has the
advantage that multiple data sources may improve the
power of the screen, and may improve the ability to
identify genes that are clinically relevant due to their
dysregulation in patient tissues. We used Oncomine™
(Compendia Bioscience, Ann Arbor, MI) [25] to com-
pare microarray data from 16 different studies [26-39]
that evaluated gene expression in normal prostate tissue
vs. PCa tissue (prostate carcinoma or prostate adenocar-
cinoma) to evaluate the candidate progression genes
identified near vector proviruses listed in Additional file 2:
Table S1. We reasoned that candidate driver genes
identified in our screen were likely to be over or under-
expressed in PCa tissue and that meta-analysis of previ-
ously published microarray studies would be a powerful
way to screen our candidates for driver genes likely to be
potential biomarkers or therapeutic targets. To evaluate
over or under-expression we used both the rank and
a multiple comparisons-corrected p-value as calcu-
lated by Oncomine™. Candidate genes with p-values < .005
and ranks less than 1000 in either the over- or under-
expression multiple comparisons were considered as
potential driver genes (Table 1). Promising candidates
identified from the androgen-independent in vitro cul-
ture were ATPAF1 (ATP synthase mitochondrial F1
complex assembly factor 1) and TRPM4 (transient re-
ceptor potential cation channel, subfamily M, member 4).
Promising candidates identified from the androgen-
independent in vivo tumor were GCOM1 (GRINL1A
complex locus 1), MEX3D (mex-3 RNA binding family
member D), and PTRF (polymerase I and transcript re-
lease factor). Three of these genes, ATPAF1, MEX3D and
TRPM4, are over-expressed in PCa tissue, while two
are under-expressed, GCOM1 and PTRF (Figure 4
and Additional file 4: Figure S2). The locations of the
five vector integrants were mapped relative to genomic
loci using the University of California, Santa Cruz (UCSC)
Genome Browser (Additional file 5: Figure S3 and
Additional file 6: Figure S4).
Validation of genes involved in AIPC by RNAi knockdown
confirms involvement of ATPAF1 and in PCa progression
To validate the effects of ATPAF1 and PTRF on androgen-
independence we used LV-mediated RNAi. For ATPAF1
and PTRF a set of commercially available pGIPZ LV vectors
targeting different sites on each gene were first screened to
find an efficient shRNA target (Additional file 7: Figure S5).
The pGIPZ vector with the most effective shRNA was then
used to transduce LNCaP cells. Cells were then cultured
with puromycin to eliminate untransduced cells. Knock-
down was confirmed by RT-PCR (Additional file 7:
Figure S5C) and then puromycin-resistant cells were
cultured under androgen-deficient conditions to select
for androgen-independence. PTRF is under-expressed
in PCa tissue, so PTRF knockdown was expected to
lead to more rapid proliferation under androgen-deficient
conditions. Conversely, ATPAF1 is overexpressed in PCa
tissue, so knockdown of this gene should impair prolifera-
tion under androgen-deficient conditions. After 31 days of
culture in androgen-deficient medium, as expected knock-
down of PTRF resulted in higher cell numbers than cells
transduced with the control vector, however the increase
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Figure 3 LV integrants are enriched in PCa susceptibility loci
after selection for androgen-independence. Lentiviral integration
sites (75) identified from LNCaP androgen-independent cultures
in vitro or tumors from castrated animals (AI-LNCaP) were mapped
relative to previously described PCa susceptibility loci (PCSL). The
frequency of these sites was compared to LNCaP cells pre-selection
(LNCaP) and to a control data set of 10,000 random sites. *indicates
significant difference of p < 0.001.
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did not reach statistical significance (p = 0.25) (Figure 5).
Knockdown of ATPAF1 resulted in significantly fewer cells
in androgen-deficient medium than the control by day 31
of culture (p < 0.05).
Discussion
PCa remains a significant health problem and a leading
cause of cancer related death in the United States and
parts of Europe [8,9]. However, many of PCa’s molecular
mechanisms remain elusive. Though treatable in its
early, androgen-dependent stages, PCa often progresses
to a lethal, untreatable, androgen-independent form.
Here, we report for the first time, a retroviral mutagen-
esis screen using a replication-incompetent LV vector to
identify genes that mediate progression to AIPC. Our
shuttle vector approach efficiently recovered integration
sites that could be rapidly mapped to genomic loci. We
observed a strong enrichment of provirus integrations in
PCa susceptibility loci when integration sites were com-
pared between transduced cells prior to culture in
androgen-deficient medium and after cells had become
androgen-independent. This suggests that integrated
vector proviruses dysregulated nearby genes that allowed
these clones to proliferate in the absence of androgen,
and provided a selective advantage resulting in their en-
richment in a polyclonal population. While this has been
widely exploited for retrovirus mutagenesis screens, we
show here for the first time that a replication-incompetent
LV can be used to identify candidate genes that mediate
AIPC. By performing meta-analysis of our data with pa-
tient data we identified 5 promising candidate AIPC genes
from 75 unique integration sites.
High-throughput gene expression studies [40-42], com-
parative genome hybridization studies [43,44], and prote-
ome studies [45-47] have previously been used to identify
PCa genes. However differentiating driver genes from pas-
senger genes using these approaches has been difficult.
Retroviral mutagenesis identifies driver genes by dysregu-
lating genes near vector proviruses that provide a selective
advantage. It also models a major mechanism for PCa,
the formation of double-strand breaks (DSBs) (Figure 6)
which can result in gene fusions such as TMPRSS-ERG
[48,49]. These gene fusions often place constitutively ac-
tive promoters next to oncogenes, resulting in activation
of an oncogene. LV-based mutagenesis can model muta-
tions caused by DSBs as we use a strong viral promoter/
enhancer to dysregulate neighboring genes, analogous to
the juxtaposition of strong promoters to nearby proto-
oncogenes (Figure 6C).
Using a replication-incompetent LV shuttle vector has
several advantages. LVs can be produced at high titer
and the vesicular stomatitis virus glycoprotein used to
pseudotype the LV has a broad tropism allowing for effi-
cient transduction of essentially any target mammalian
cell. Thus our approach can be used to identify genes in-
volved in numerous oncogenic processes. For example,
such a screen could be used to identify genes involved in
the progression to metastatic breast cancer. Further, the
approach can be used to identify genes involved in virtu-
ally any biological process that involves cells that un-
dergo a selective pressure. A novel advantage of our
approach is in the method of recovery of the provirus in-
tegration site. Previous mutagenesis screens have used
PCR to detect proviral integrations but PCR is limited in
its ability to identify rare or poorly amplified insertions
[1]. Additionally, PCR sequence read lengths are shor-
ter than those recovered using a shuttle vector rescue
technology [21]. The longer sequence reads provided by
shuttle vector allow for a more accurate localization of
the provirus integration. There are some limitations to
the design of our mutagenesis screen. The LV used con-
tains self-inactivating (SIN) LTRs with modified U3 re-
gion in the 3′ long-terminal-repeat (LTR) sequences and
with deleted viral enhancers. The lack of transcription-
ally active LTRs in SIN LVs reduces genotoxicity relative
to lentiviral or gammaretroviral vectors with an intact
LTR [20]. Future studies will explore the effect of retro-
viral vector type and design on the mutagenic potential.
Our screen identified five candidate PCa progression
genes; ATPAF1, GCOM1, MEX3D, PTRF, and TRPM4.
TRPM4 has been associated with the development of
a cancer phenotype, particularly with cell proliferation
Table 1 Candidate AIPC genes
Gene Source In gene/distance PCSL Expression p-value
ATPAF1 In vitro yes none over 0.002
GCOM1 In vivo yes none under 0.003
MEX3D In vivo 32,561 19p13.3 over 9.70E-04
PTRF In vivo 62,474 17q21-22 under 0.003
TRPM4 In vitro yes near 19q13.4 over 1.13E-04
Candidate AIPC genes identified from provirus integration sites recovered from both the in vitro mutagenesis screen and the in vivo subcutaneous tumor model.
Source indicates whether the gene was identified from the in vitro screen or the in vivo screen. In gene/distance indicates whether the LV provirus was within the
gene transcription unit, or if outside the transcription unit indicates the distance in base pairs from the proviral integration to the transcription start site of the
gene. PCSL indicates if the provirus was within or near a PCa susceptibility locus. Expression indicates if the gene was over or under-expressed in PCa tissue using
the Oncomine™ database. Rank is the Oncomine™ ranking of over or under-expressed genes. p-value is the Oncomine™ p-value for over or under-expression.
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and tumor progression [50,51], and has been specifically
shown to enhance cell proliferation through up-regulation
of the β-catenin signaling pathway [50,52]. GCOM1 is a
locus with a naturally occurring read-through transcrip-
tion event, with one transcript encoding a fusion protein
[53]. Interestingly GCOM1 was identified as an estrogen
receptor β (ERβ) target gene [54]. Estrogen receptors ap-
pear to play an important role in PCa and ERβ is ex-
pressed in the prostate gland [55]. ERβ is the main target
for phytoestrogens, and may play a role in the difference
in incidence of PCa in the Western world compared to
Asia where the intake of soy-based, phytoestrogen-rich
food is higher [55]. PTRF has been associated with a num-
ber of different functions in the prostate and in cancer. In
PCa, PTRF expression has been shown to alter the aggres-
siveness of the cancer [56]. PTRF has also been shown to
be decreased significantly in LNCaP and PC3 cells and in
cancer tissue [57]. PTRF is involved in the formation of
caveolae, invaginations of the plasma membrane [58,59].
PTRF is also involved in localization of caveolin-1, which
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Figure 4 Differential expression in normal prostate tissue vs.
PCa tissue for candidate AIPC genes. Oncomine™ (Compendia
Bioscience, Ann Arbor, MI) was used for analysis and visualization.
The Oncomine™ database was queried using gene names for
ATPAF1, GCOM1, MEX3D, PTRF, and TRPM4 using the Cancer vs.
Normal Analysis, and selecting PCa vs. Normal analysis. This provides
gene expression levels in healthy prostate tissue (left side, control),
and prostate carcinoma or prostate adenocarcinoma tissue samples
(right side, PCa). The data is represented here as waterfall plots for
each different gene.
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Figure 5 Validation using LV-mediated knockdown. LNCaP cells
were transduced with a pGIPZ lentiviral vector expressing a shRNA
targeting either ATPAF1, PTRF, or a control empty vector. Vector-
exposed cells were selected using puromycin to eliminate
untransduced cells. Transduced cells were then cultured in
androgen-deficient medium to determine if knockdown of ATPAF1
or PTRF affected growth.
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is involved in PCa severity, aggressiveness, metastasis, and
androgen sensitivity [58]. Additionally, PTRF is under-
expressed in PCa, and its expression can actually attenuate
PCa disease severity and aggressiveness [58].
While these genes have been previously associated
with cancer or prostate physiology, our screen was also
able to identify novel candidate PCa progression genes.
MEX3D, is a member of the Mex-3 subfamily of con-
served RNA-binding proteins, which are involved in
post-transcriptional regulation [60]. MEX3D was previ-
ously associated with chemotherapy-induced oral muco-
sitis in acute myeloid leukemia patients [61]. ATPAF1,
another novel target, encodes an assembly factor for the
F1 component of the mitochondrial ATP synthase,
which is required for assembly of the ATP synthase F1
complex in oxidative phosphorylation [62]. ATPAF1 is
widely expressed in host tissues, but to our knowledge
has never been specifically linked to cancer. However,
another mitochondrial protein involved in mitochondrial
oxidative phosphorylation, ATPase inhibitory factor 1
(ATPIF1) mediates the metabolic shift of cancer cells to
a Warburg phenotype and has been identified as a
promising predictive marker for clinical outcome in
breast and colon cancer [63].
Our data suggests an involvement of both PTRF and
ATPAF1 in AIPC. ATPAF1 knockdown resulted in sig-
nificantly decreased growth relative to controls, however
the increase in growth was not significant for PTRF
knockdown. PTRF expression is decreased in PCa cells,
including LNCaP and PC-3 [57]. We speculate that be-
cause the level of PTRF expression in LNCaP cells is
normally low, that any effect from knockdown by RNAi
is limited. Clearly further experiments are warranted to
confirm the role of PTRF and ATPAF1 in AIPC, but our
study is the first to our knowledge to implicate ATPAF1
in AIPC.
Conclusions
We utilized a replication-incompetent shuttle LV as an
insertional mutagen to identify genes involved in the
progression to AIPC. This approach has proved effective
for use in PCa, showing enrichment of proviral integ-
rations near PCa susceptibility loci and identifying 5
potential driver genes, 1 of which was validated. Our
approach has broad potential applications for cancer
gene discovery, and for interrogating diverse biological
and disease processes.
Methods
Cell line culture, vector production and transduction
The androgen-dependent human prostate carcinoma cell
line LNCaP-FGC (ATCC CRL-1740) was cultured in
RPMI-1640 supplemented with 10% FBS (Atlanta Bio-
logicals, Lawrenceville, GA) at 37°C in 5% CO2. The LV
shuttle vector, LV-SFFVEGFP, has self-inactivating long
terminal repeats (LTRs), an internal spleen focus-forming
virus promoter driving EGFP expression, and R6Kγ origin
of replication and a neomycin phosphotransferase gene.
Vesicular stomatitis virus glycoprotein pseudotyped vec-
tor stocks were made by PEI-mediated transfection of
HEK-293T cells as previously described [64]. Functional
titers were determined by transduction of HT-1080
// //
// //Y
dysregulated expression of gene Y
from strong viral enhancer
promotes prostate cancer progression
// //
Y
// //X
X
dysregulated expression of gene Y
from gene X promoter after DSB -induced rearrangement
promotes prostate cancer progression
SFFV
regulated expression of gene Y:
no prostate cancer progression
DSB DSB
Y
wt gene X locus wt gene Y locus
DSB-induced rearrangement brings
gene Y under control of gene X promoter
A
C Integrated shuttle vector provirus dysregulates gene Y
B
Figure 6 Shuttle vector mutagenesis models a major mechanism whereby DSB-induced rearrangements dysregulate genes. In panel A
two loci are shown where a strong promoter expresses gene X and a weaker regulated promoter expresses gene Y. In panel B a DSB-induced
rearrangement places gene Y under the control of the gene X promoter, dysregulating gene Y and thereby promoting PCa progression. In panel
C an integrated shuttle vector provirus enhances expression of gene Y promoting PCa progression.
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fibrosarcoma cells. Cells were cultured for 14 days post
vector exposure prior to use in experiments.
Shuttle vector rescue in bacteria, identification of
integration sites and clonality evaluation
Genomic DNA was isolated using the Puregene Cell &
Tissue kit (Qiagen Inc., Valencia, CA) and was sheared
using a Hydroshear (DigiLab Inc., Marlborough, MA).
The ends of the DNA were repaired using the Termin-
ator End Repair Kit (Lucigen Corporation, Middleton,
WI). Sheared fragments were ligated using T4 DNA Lig-
ase (New England Biolabs, Inc., Ipswich, MA) and trans-
formed by electroporation. Shuttle vector plasmids from
kanamycin-resistant colonies were sequenced using
primers specific to the LV LTR. A total of 288 colonies
were sequenced for the in vitro cultures and 96 colonies
were sequenced for each tumor. The junction between
the integrated provirus and the chromosome was identi-
fied and integration sites in the human genome (hg19)
were determined using PERL bioinformatics programs
[21] that invoke a standalone BLAT program [65]. To be
considered as an integration site the alignment score
had to have a canonical LTR-chromosome junction and
meet additional strict criteria as previously described
[21]. A control dataset of 10,000 random sites was gen-
erated as previously described [65]. The Schnabel me-
thod of multiple-census mark-recapture was used to
approximate the number of unique integration sites in
the entire population prior to selection for androgen in-
dependence [66,67].
In vitro androgen-independent culture
Control and LV-SFFVEGFP transduced LNCaP cells were
maintained in RPMI-1640 supplemented with 9.75% char-
coal/dextran-treated FBS (CT-FBS) and 0.25% FBS (At-
lanta Biologicals, Lawrenceville, GA), before being moved
to and maintained in RPMI-1640 supplemented with 10%
CT-FBS. Cells were counted using a Cellometer Auto T4
(Nexcelom Bioscience Inc., Lawrence, MA) and replated
approximately every 2-3 weeks.
In vivo model of PCa
All protocols involving the use of animals were approved
by the Washington State University Institutional Animal
Care and Use Committee and institutional guidelines for
the humane use of animals in research were followed.
Male 4-8 week old NSG mice were obtained from The
Jackson Laboratory (Bar Harbor, Maine). LV-mutagenized
or control LNCaP cells were inoculated via subcuta-
neous injection. Between 1-5×106 cells were suspen-
ded in 100 μL of RPMI-1640 plus 5% FBS plus 100 μL
Matrigel (BD Biosciences, Bedford, MA) and injected via a
25 gauge needle into the right flank. Tumors were vis-
ually monitored or measured once to twice weekly
and their volumes were calculated using the formula
L×W×H×0.5236 [17].
To select for androgen-independent tumor growth
in vivo, mice were castrated via the scrotal approach.
Mice were anesthetized with isoflurane or ketamine and
xylazine (80mg/kg and 6mg/kg, respectively). When tu-
mors reached volumes larger than the tumor size prior
to castration, mice were sacrificed, tumor tissue was
harvested. Genomic DNA was obtained from tumor tis-
sue using the Puregene Cell & Tissue kit (Qiagen Inc.,
Valencia, CA).
Validation of the effect of target genes on AIPC using
LV-mediated RNAi
pGIPZ lentiviral shRNA vector sets of 3-6 shRNA
vectors were obtained from Thermo Fisher Scientific
(Waltham, MA) for the selected target genes. Gene
knockdown was evaluated using the psiCHECK™-2 sys-
tem (Promega Corporation, Madison, WI) using a syn-
thesized sequence (GenScript USA, Inc., Piscataway, NJ)
containing target sites for each target gene shRNA
cloned into the psiCHECK™-2 vector. psiCHECK™-2 vec-
tors containing these target fragments were co-
transfected with pGIPZ shRNA vector sets for each spe-
cific target gene. The efficiency of the knockdown for
each shRNA for each gene was determined with the
Dual-Luciferase® Reporter Assay System (Promega Cor-
poration, Madison, WI). The shRNA which demonstrated
the most efficient knockdown of luciferase activity for
each target gene was selected. Vesicular stomatitis virus
glycoprotein pseudotyped vector stocks were made by
PEI-mediated transfection of HEK-293T cells as described
above. LNCaP cells for in vitro validation were transduced
at a multiplicity of infection of 5, selected in 2.5 μg/mL
puromycin, and expanded. RT-PCR was used to quantitate
the expression levels of these genes in the pGIPZ trans-
duced LNCaP cells. Total RNA from LNCaP cells trans-
duced with a LV carrying a shRNA sequence against the
candidate genes or vector with no shRNA (EV) was iso-
lated using TRIzol reagent (Invitrogen, Carlsbad, CA).
cDNA was synthesized from the total RNA using Tran-
scription First Strand Synthesis Kit (Roche Diagnostics,
Indianapolis, IN). cDNA was used as a template to
amplify gene specific products using primers ATPAF1
(forward: 5′- GCCAACCAAGTTCAGCTCTT-3′ and
reverse 5′-GGTTCTGGGCACATTTCAGT-3′), PTRF
(forward: 5′-GAAGAGCTGATCAAGTCGGACC-3′ and
reverse: 5′-GCTTCACTTCATCCTGGTAGATCA-3′) and
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; for-
ward: 5′-ATCCCATCACCATCTTCCAG-3′ and reverse:
5′- CCATCACGCCACAGTTTCC-3′). Transduced puro-
mycin-resistant LNCaP cells were cultured in androgen-
deficient medium and cell number determined as de-
scribed above.
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Statistical analysis
To assess the enrichment of proviruses in PCa suscepti-
bility loci after selection for androgen-independence, a
χ2 test of the frequency of integration sites was used. To
assess the effects of shRNA knockdown of PTRF and
ATPAF1 on androgen-independence a Student’s t-test
was used.
Additional files
Additional file 1: Figure S1. Determining the clonality of LV integrants.
Additional file 2: Table S1. Proviral integration sites identified from
both in vitro and in vivo androgen-independent samples. The in vitro
androgen-independent culture SVM-A led to the identification of 21
unique integration sites. The in vivo androgen-independent subcutaneous
(s.c.) tumors led to the identification of 54 unique integration sites. In total,
75 unique integration sites were identified.
Additional file 3: Table S2. PCa susceptibility loci.
Additional file 4: Figure S2. Oncomine meta-analysis of expression in
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